Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Cryptococcosis is a serious fungal infection, particularly in immunocompromised individuals.
• Standard treatments like amphotericin B have limitations and potential toxicities.

Purpose of the Study:

• To evaluate the efficacy and safety of itraconazole for treating various forms of cryptococcosis.
• To compare itraconazole's effectiveness against established antifungal therapies.

Main Methods:

• A study involving 33 patients (32 immunocompromised) with diverse cryptococcal infections.
• Therapy involved oral itraconazole (200 mg twice daily), with monitoring via clinical response, cultures, and antigen testing.
• In vitro susceptibility testing of Cryptococcus neoformans isolates to itraconazole was performed.

Main Results:

• Excellent outcomes were observed for cryptococcemia (100% abolition) and localized infections (pulmonary, osteomyelitis, soft-tissue; 100% response).
• For cryptococcal meningitis, 65% of assessable patients achieved complete response, with notable success (71% complete response) in AIDS patients receiving itraconazole monotherapy.
• Relapses occurred in 20% of meningitis patients, often linked to noncompliance, prior treatment failure, or severe disease. In vitro, 91% of isolates were susceptible to itraconazole.

Conclusions:

• Itraconazole demonstrates significant efficacy in treating cryptococcosis, including challenging cases of cryptococcal meningitis, even in severely immunocompromised patients.
• Despite limited cerebrospinal fluid penetration, itraconazole's effectiveness in meningitis suggests critical tissue penetration.
• Itraconazole presents a promising oral therapeutic option for cryptococcosis, potentially offering an alternative to intravenous amphotericin B.